Atossa Therapeutics, Inc. Common Stock ATOS
i
Market datapartial · fetched 2026-11-11T05:54:22.812Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T22:09:31.397960319Z
FundamentalsAlpha Vantage · unavailable
Atossa Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.43 | 642.6% | 56.7% | |||
| 25Δ | 1.67 | 557.9% | 45.9% | |||
| 30Δ | 1.90 | 473.2% | 35.1% | |||
| 35Δ | 2.07 | 424.3% | 28.8% | |||
| 40Δ | 2.19 | 400.9% | 25.7% | |||
| 45Δ | 2.31 | 377.4% | 22.6% | |||
| 50Δ | 2.38 | 280.1% | 26.4% | 2.43 | 354.0% | 19.6% |
| 55Δ | 2.26 | 289.7% | 23.0% | 2.55 | 330.5% | 16.5% |
| 60Δ | 2.14 | 299.4% | 19.7% | 2.67 | 307.0% | 13.4% |
| 65Δ | 2.02 | 309.0% | 16.3% | 2.79 | 283.6% | 10.4% |
| 70Δ | 2.91 | 260.1% | 7.3% | |||
| 75Δ | 3.12 | 249.5% | 4.8% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.43
- IV
- 642.6%
- B/E move
- 56.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.67
- IV
- 557.9%
- B/E move
- 45.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.90
- IV
- 473.2%
- B/E move
- 35.1%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.07
- IV
- 424.3%
- B/E move
- 28.8%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.19
- IV
- 400.9%
- B/E move
- 25.7%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.31
- IV
- 377.4%
- B/E move
- 22.6%
50Δ
- Pseudo strike
- 2.38
- IV
- 280.1%
- B/E move
- 26.4%
- Pseudo strike
- 2.43
- IV
- 354.0%
- B/E move
- 19.6%
55Δ
- Pseudo strike
- 2.26
- IV
- 289.7%
- B/E move
- 23.0%
- Pseudo strike
- 2.55
- IV
- 330.5%
- B/E move
- 16.5%
60Δ
- Pseudo strike
- 2.14
- IV
- 299.4%
- B/E move
- 19.7%
- Pseudo strike
- 2.67
- IV
- 307.0%
- B/E move
- 13.4%
65Δ
- Pseudo strike
- 2.02
- IV
- 309.0%
- B/E move
- 16.3%
- Pseudo strike
- 2.79
- IV
- 283.6%
- B/E move
- 10.4%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.91
- IV
- 260.1%
- B/E move
- 7.3%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.12
- IV
- 249.5%
- B/E move
- 4.8%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 139.39% | |
| 155.22% | |
| 140.36% | |
| 131.71% | |
| 151.30% | |
| 168.47% | |
| 184.38% |
Biotechnology
AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is…
More →AURA
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its unique virus-like particle (VLP) technology. The…
More →AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United…
More →AVBP
Description unavailable
More →AVIR
Description unavailable
More →AVLN
Description unavailable
More →